Although our study focused on the Akt/mTOR/FoxO3a pathway, future research should examine whether SGE and kirenol also influence these pathways, which could provide a more comprehensive understanding of their therapeutic effects in skeletal muscle atrophy. The gene discussed is FOXO3; the disease is muscular atrophy.